Hmong
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Cov khoom Categories
Cov khoom tshwj xeeb
Lenopril ntsiav tshuaj txhawb kev tswj ntshav siab thiab mob plawv

Lenopril ntsiav tshuaj txhawb kev tswj ntshav siab thiab mob plawv
Telmisartan Zoo dua antihypertensive Tiv thaiv lub raum

Telmisartan Zoo dua antihypertensive Tiv thaiv lub raum
Flumazenil A Selective GABAA Receptor Antagonist thiab nws cov kev siv kho mob

Flumazenil A Selective GABAA Receptor Antagonist thiab nws cov kev siv kho mob
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
Dabrafenib Lub Hom Phiaj Kev Kho Mob rau BRAF-Mutated Cancers

Dabrafenib Lub Hom Phiaj Kev Kho Mob rau BRAF-Mutated Cancers
Tirzepatide Dual GLP-1 thiab GIP Receptor Agonist rau Kev Tswj Qhov hnyav thiab Glycemic Control

Tirzepatide Dual GLP-1 thiab GIP Receptor Agonist rau Kev Tswj Qhov hnyav thiab Glycemic Control
Cisapride Gastric Stimulant rau Indigestion thiab Digestive Disorders

Cisapride Gastric Stimulant rau Indigestion thiab Digestive Disorders
YK-11 Muaj peev xwm SARM rau Lub Tsev Muscle, Lub Zog Tau Txais, thiab Myostatin Inhibition

YK-11 Muaj peev xwm SARM rau Lub Tsev Muscle, Lub Zog Tau Txais, thiab Myostatin Inhibition
Ostarine (MK-2866) Ntau yam SARM rau Cov leeg nqaij loj hlob, rog poob, thiab lub cev rov ua haujlwm

Ostarine (MK-2866) Ntau yam SARM rau Cov leeg nqaij loj hlob, rog poob, thiab lub cev rov ua haujlwm
MK-677 Unique Compound rau cov leeg loj hlob, kev ua siab ntev, thiab rov qab los

MK-677 Unique Compound rau cov leeg loj hlob, kev ua siab ntev, thiab rov qab los
0102 ib0304 ib05
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Nqe: USD 8-15 / g

  • Khoom npe Trametinib
  • CAS Nr. 871700-17-3
  • MF C26H23FIN5O4
  • MW 615.402623
  • Qhov ntom 1.743 ib
  • Melting point 293-303 ° C
Tiv tauj peb
cov khoom paub meej

Cov lus piav qhia ntxaws

Trametinib yog ib qho muaj zog thiab xaiv kinase inhibitor feem ntau siv rau hauv kev kho mob uas tsis tuaj yeem kho lossis metastatic melanoma nrog BRAF V600 kev hloov pauv, nrog rau cov hom tshwj xeeb ntawm cov qib siab lossis metastatic uas tsis yog mob qog noj ntshav me me. Kab lus no tshawb txog cov txheej txheem ntawm kev nqis tes ua, kev tshuaj ntsuam xyuas, thiab cov txiaj ntsig ntawm trametinib hauv kev kho mob ntawm BRAF V600 kev hloov pauv-zoo mob qog noj ntshav.

I. Nkag siab Trametinib:
A. Qhov ncauj, muaj zog, thiab xaiv kinase inhibitor
B. belongs rau chav kawm MEK inhibitors
C. Blocks kinase kev ua ntawm MEK1 thiab MEK2
D. Inhibits downstream ERK1 thiab ERK2 signaling

II. Clinical Indications:
A. Unreectable lossis metastatic melanoma harboring BRAF V600 kev hloov pauv:
Kev sib xyaw ua ke nrog dabrafenib mesylate
B. Postoperative adjuvant therapy rau BRAF V600 mutation-positive melanoma:
Adjuvant kho nrog dabrafenib mesylate tom qab ua tiav resection

17161152266097 ib

III. Lub luag hauj lwm nyob rau hauv Non-Small Cell Lung Cancer:

A. Cov qog nqaij hlav qog nqaij hlav tsis me me yog qhov ua rau muaj mob thiab tuag taus

B. BRAF gene mutation rate thiab prevalence ntawm BRAF V600E mutation

C. Trametinib cov nyhuv inhibitory ntawm BRAF V600 hloov pauv-zoo melanoma hlwb


IV. Mechanism ntawm Action:

A. Reversible inhibition ntawm mitogen-activated extracellular signal-regulated kinase (MEK) 1 thiab MEK2

B. Kev cuam tshuam rau txoj kev MAPK thiab MEK protein

C. Inhibition ntawm cell proliferation thiab downstream ERK txoj kev


V. Postoperative Adjuvant Therapy:

A. Cov txiaj ntsig ntawm kev npaj ua ke nrog kev kho mob nrog Dabrafenib thiab Trametinib

B. Lub sij hawm ntev, ruaj khov tsis muaj sia nyob (RFS) cov txiaj ntsig hauv cov neeg mob uas muaj kev pheej hmoo siab III BRAF hloov pauv-zoo melanoma cov neeg mob



Trametinib, lub hom phiaj kinase inhibitor, qhia tau hais tias muaj txiaj ntsig zoo hauv kev kho mob ntawm BRAF V600 kev hloov pauv-zoo mob qog noj ntshav, tshwj xeeb tshaj yog tsis tuaj yeem kho lossis metastatic melanoma thiab qee hom mob qog noj ntshav ntawm lub ntsws. Nws cov txheej txheem ntawm kev ua, inhibiting MEK1 thiab MEK2 kinase kev ua haujlwm, ua rau qis qis ERK txoj hauv kev inhibition thiab kev tawm tsam ntawm cell proliferation. Trametinib, ua ke nrog dabrafenib mesylate, muab cov txiaj ntsig kho mob hauv ob qho tib si qib siab thiab cov chaw kho mob rau BRAF V600 hloov pauv-zoo melanoma cov neeg mob.
Tiv tauj peb rau cov lus qhia tshuaj thiab cov ntaub ntawv lag luam wholesale nqe los txhim kho kev saib xyuas neeg mob.

Specification

171611254334271z